Selected research
Industry Growth & Trends
Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Post-Polycythemia Vera Myelofibrosis (PPV-MF) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Post-Polycythemia Vera Myelofibrosis (PPV-MF) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Post-Polycythemia Vera Myelofibrosis (PPV-MF) is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Post-Polycythemia Vera Myelofibrosis (PPV-MF) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Post-Polycythemia Vera Myelofibrosis (PPV-MF) market include Novartis AG, Merck & Co Inc, AbbVie Inc, Sun Pharma Advanced Research Company Ltd, Promedior Inc, NS Pharma Inc, MEI Pharma Inc, MedImmune LLC and JW Pharmaceutical Corp, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Post-Polycythemia Vera Myelofibrosis (PPV-MF) market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Post-Polycythemia Vera Myelofibrosis (PPV-MF) market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Post-Polycythemia Vera Myelofibrosis (PPV-MF) market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Post-Polycythemia Vera Myelofibrosis (PPV-MF).
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Post-Polycythemia Vera Myelofibrosis (PPV-MF) market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market by Company
Novartis AG
Merck & Co Inc
AbbVie Inc
Sun Pharma Advanced Research Company Ltd
Promedior Inc
NS Pharma Inc
MEI Pharma Inc
MedImmune LLC
JW Pharmaceutical Corp
Italfarmaco SpA
Incyte Corp
Gilead Sciences Inc
F. Hoffmann-La Roche Ltd
CTI BioPharma Corp
Celgene Corp
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Segment by Type
Idelalisib
Givinostat
Glasdegib
Durvalumab
IMG-7289
Others
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Segment by Application
Hospital
Clinic
Others
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Post-Polycythemia Vera Myelofibrosis (PPV-MF) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Post-Polycythemia Vera Myelofibrosis (PPV-MF) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Post-Polycythemia Vera Myelofibrosis (PPV-MF).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Post-Polycythemia Vera Myelofibrosis (PPV-MF) companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Idelalisib
- Givinostat
- Glasdegib
- Durvalumab
- IMG-7289
- Others
Applications
- Hospital
- Clinic
- Others
Companies covered
- Novartis AG
- Merck & Co Inc
- AbbVie Inc
- Sun Pharma Advanced Research Company Ltd
- Promedior Inc
- NS Pharma Inc
- MEI Pharma Inc
- MedImmune LLC
- JW Pharmaceutical Corp
- Italfarmaco SpA
- Incyte Corp
- Gilead Sciences Inc
- F. Hoffmann-La Roche Ltd
- CTI BioPharma Corp
- Celgene Corp
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Region (2021-2032)
- 1.4.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Region (2021-2026)
- 1.4.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Region (2027-2032)
- 1.5 Key Regions Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size (2021-2032)
- 1.5.1 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Growth Rate (2021-2032)
- 1.5.4 South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Growth Rate (2021-2032)
2 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market by Type
- 2.1 Type Introduction
- 2.1.1 Idelalisib
- 2.1.2 Givinostat
- 2.1.3 Glasdegib
- 2.1.4 Durvalumab
- 2.1.5 IMG-7289
- 2.1.6 Others
- 2.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Type
- 2.2.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Overview by Type (2021-2032)
- 2.2.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Forecasted by Type (2027-2032)
- 2.3 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Regions
- 2.3.1 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Breakdown by Type (2021-2026)
3 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market by Application
- 3.1 Type Introduction
- 3.1.1 Hospital
- 3.1.2 Clinic
- 3.1.3 Others
- 3.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Application
- 3.2.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Overview by Application (2021-2032)
- 3.2.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Forecasted by Application (2027-2032)
- 3.3 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Regions
- 3.3.1 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Trends
- 4.2 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Drivers
- 4.3 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Opportunities and Challenges
- 4.4 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (2021-2026)
- 5.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Key Company Headquarters & Area Served
- 5.4 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Company, Product Type & Application
- 5.5 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Players Market Share by Revenue in 2025
- 5.6.3 2025 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Novartis AG
- 6.1.1 Novartis AG Company Information
- 6.1.2 Novartis AG Business Overview
- 6.1.3 Novartis AG Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Novartis AG Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 6.1.5 Novartis AG Recent Developments
- 6.2 Merck & Co Inc
- 6.2.1 Merck & Co Inc Company Information
- 6.2.2 Merck & Co Inc Business Overview
- 6.2.3 Merck & Co Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Merck & Co Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 6.2.5 Merck & Co Inc Recent Developments
- 6.3 AbbVie Inc
- 6.3.1 AbbVie Inc Company Information
- 6.3.2 AbbVie Inc Business Overview
- 6.3.3 AbbVie Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 AbbVie Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 6.3.5 AbbVie Inc Recent Developments
- 6.4 Sun Pharma Advanced Research Company Ltd
- 6.4.1 Sun Pharma Advanced Research Company Ltd Company Information
- 6.4.2 Sun Pharma Advanced Research Company Ltd Business Overview
- 6.4.3 Sun Pharma Advanced Research Company Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Sun Pharma Advanced Research Company Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 6.4.5 Sun Pharma Advanced Research Company Ltd Recent Developments
- 6.5 Promedior Inc
- 6.5.1 Promedior Inc Company Information
- 6.5.2 Promedior Inc Business Overview
- 6.5.3 Promedior Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Promedior Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 6.5.5 Promedior Inc Recent Developments
- 6.6 NS Pharma Inc
- 6.6.1 NS Pharma Inc Company Information
- 6.6.2 NS Pharma Inc Business Overview
- 6.6.3 NS Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 NS Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 6.6.5 NS Pharma Inc Recent Developments
- 6.7 MEI Pharma Inc
- 6.7.1 MEI Pharma Inc Company Information
- 6.7.2 MEI Pharma Inc Business Overview
- 6.7.3 MEI Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 MEI Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 6.7.5 MEI Pharma Inc Recent Developments
- 6.8 MedImmune LLC
- 6.8.1 MedImmune LLC Company Information
- 6.8.2 MedImmune LLC Business Overview
- 6.8.3 MedImmune LLC Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 MedImmune LLC Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 6.8.5 MedImmune LLC Recent Developments
- 6.9 JW Pharmaceutical Corp
- 6.9.1 JW Pharmaceutical Corp Company Information
- 6.9.2 JW Pharmaceutical Corp Business Overview
- 6.9.3 JW Pharmaceutical Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 JW Pharmaceutical Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 6.9.5 JW Pharmaceutical Corp Recent Developments
- 6.10 Italfarmaco SpA
- 6.10.1 Italfarmaco SpA Company Information
- 6.10.2 Italfarmaco SpA Business Overview
- 6.10.3 Italfarmaco SpA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Italfarmaco SpA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 6.10.5 Italfarmaco SpA Recent Developments
- 6.11 Incyte Corp
- 6.11.1 Incyte Corp Company Information
- 6.11.2 Incyte Corp Business Overview
- 6.11.3 Incyte Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Incyte Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 6.11.5 Incyte Corp Recent Developments
- 6.12 Gilead Sciences Inc
- 6.12.1 Gilead Sciences Inc Company Information
- 6.12.2 Gilead Sciences Inc Business Overview
- 6.12.3 Gilead Sciences Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Gilead Sciences Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 6.12.5 Gilead Sciences Inc Recent Developments
- 6.13 F. Hoffmann-La Roche Ltd
- 6.13.1 F. Hoffmann-La Roche Ltd Company Information
- 6.13.2 F. Hoffmann-La Roche Ltd Business Overview
- 6.13.3 F. Hoffmann-La Roche Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 F. Hoffmann-La Roche Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 6.13.5 F. Hoffmann-La Roche Ltd Recent Developments
- 6.14 CTI BioPharma Corp
- 6.14.1 CTI BioPharma Corp Company Information
- 6.14.2 CTI BioPharma Corp Business Overview
- 6.14.3 CTI BioPharma Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Global Share and Gross Margin (2021-2026)
- 6.14.4 CTI BioPharma Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 6.14.5 CTI BioPharma Corp Recent Developments
- 6.15 Celgene Corp
- 6.15.1 Celgene Corp Company Information
- 6.15.2 Celgene Corp Business Overview
- 6.15.3 Celgene Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Global Share and Gross Margin (2021-2026)
- 6.15.4 Celgene Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 6.15.5 Celgene Corp Recent Developments
7 North America
- 7.1 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2021-2026)
- 7.3 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2021-2026)
- 8.3 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2021-2026)
- 10.3 South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst